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Autophagy is a lysosomal-driven catabolic process that contributes to preserve cell and tissue homeostases through
the regular elimination of damaged, aged and redundant self-constituents. In normal cells, autophagy protects from
DNA mutation and carcinogenesis by preventive elimination of pro-oxidative mitochondria and protein aggregates.
Mutations in oncogenes and oncosuppressor genes dysregulate autophagy. Up-regulated autophagy may confer
chemo- and radio-resistance to cancer cells, and also a pro-survival advantage in cancer cells experiencing oxygen
and nutrient shortage. This fact is the rationale for using autophagy inhibitors along with anti-neoplastic therapies.
Yet, aberrant hyper-induction of autophagy can lead to cell death, and this phenomenon could also be exploited
for cancer therapy. The actual level of autophagy in the cancer cell is greatly affected by vascularization,
inflammation, and stromal cell infiltration. In addition, small non-coding microRNAs have recently emerged as
important epigenetic modulators of autophagy. The present review focuses on the potential involvement of
macroautophagy, and on its genetic and epigenetic regulation, in ovarian cancer pathogenesis and progression.
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Ovarian cancer ranks as the fifth leading cause of
cancer-related deaths among women, and the leading
cause of death from gynecological cancer [1]. The dif-
ficulty to diagnose the disease at early stage and the
persistence of dormant, drug-resistant cancer cells that
cause relapse, are the primary reasons for the high
mortality rate in ovarian cancer patients [2]. First-line
therapy for advanced stage disease includes maximal
surgical debulking followed by platinum/taxane chemo-
therapy, which attains initial response rates of over
80% [3]. However, most patients will eventually relapse
with chemoresistant tumors. The propensity to trigger
a program of epithelial-to-mesenchymal transition, the
over-expression of drug efflux transporters and the
persistence of dormant cancer stem cells are the prin-
cipal factors that determine the recurrence and pro-
gression of ovarian cancer. The poor prognosis in
ovarian cancer patients poses the urge to identify novel* Correspondence: isidoro@med.unipmn.it
1Laboratory of Molecular Pathology and Nanobioimaging, Department of
Health Sciences, Novara, Italy
4Department of Health Sciences, Università del Piemonte Orientale “A.
Avogadro”, Via Solaroli 17, 28100, Novara, Italy
Full list of author information is available at the end of the article
© 2012 Peracchio et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand more reliable (in terms of sensitivity and specificity)
biomarkers for the detection of the disease in its (very)
early stage, for monitoring the response to treatments,
and possibly for targeted molecular therapy [4]. Recently,
autophagy dysregulation in cancer cells has been blamed
as a possible cause of dormancy and of resistance to
radio- and chemotherapeutic treatments, and proteins
involved in the regulation of this process are being con-
sidered as targets for anticancer molecular therapy. In
this review, we discuss the involvement of (macro)autop-
hagy in the pathogenesis of ovarian cancer, and on the
genetic and epigenetic factors that potentially regulate
this process. We also discuss the clinical implications of
the role of autophagy in ovarian cancer for diagnosis,
prognosis and therapy purposes.Morphology of autophagy at a glance
Autophagy literally means (from Greek) ‘self-eating’, and
refers to a cellular process committed to the lysosomal
degradation of self constituents [5]. So far, three different
types of autophagy (macroautophagy, microautophagy
and chaperon-mediated autophagy) have been described,
which essentially differ for the mechanism through
which the target substrates gain access to the lysosomalral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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referred to as autophagy), macromolecular aggregates,
portion of cytoplasm, membranes and entire organelles
are sequestered within newly formed vesicles (named
autophagosomes) that subsequently fuse with lysosomes
[6]. In the case of microautophagy, cytoplasmic material
and organelles are directly internalized by the lysosome
through invagination of the lysosomal membrane [7]. In
the case of chaperon-mediated autophagy, cytoplasmic
proteins bearing the consensus sequence KFERQ at the
C-terminus are assisted to enter the lysosome by the
chaperon Hsc70, which interacts with the lysosomal
membrane protein Lamp2A [8]. Schematically, three
main operational steps characterize the autophagy
process (Figure 1): (1) sequestration of the material into
a newly formed vesicle; (2) fusion of this vesicle with
lysosomal organelles; and (3) degradation of the material
and recycling of the substrates. These steps have beenFigure 1 Flow-chart showing the three principal steps of the (macro)a
from a pre-existing isolation membrane and terminates with the formation
complex of the autophagy interactome, and some other beclin 1 interacto
inhibited by Wortmannin, LY294002 or 3-methyadenine (3MA). The interact
III complex. JNK-mediated phosphorylation of bcl-2 or DAPk-mediated pho
thus favors the formation of the autophagy interactome. During vesicle nu
the internal and external membrane of the autophagosome. Atg4 plays a c
(namely, atg3, atg5, atg7 and atg12) participate in the process of lipidation
of LC3 II. The second step consists in the docking and fusion of the autoph
autophagolysosome. This step can be inhibited by drugs that increase the
in the degradation of the autophagic vesicle and of its cargo by acid hydro
FFA, free fatty acids) for reutilization. The lysosomal degradation step can b
raising the internal pH.widely characterized at morphological level [9], and new
guidelines for their assessment have been recently
released [10]. The hallmark of autophagosome formation
is represented by the insertion within the inner and
outer layers of the vesicle of LC3 II (isoform II of Light
Chain), which is generated from the precursor Micro-
tubule Associated Protein (MAP-LC3) by partial prote-
olysis and subsequent lipidation at its C-terminus [11].
The fusion of the autophagosome with late endosomes
and lysosomes can be assessed by co-labeling LC3 and
Lamp1 (the latter is a Lysosomal Associated Membrane
Protein). Another means to look at the autophagy flux is
to follow the degradation of p62/SQSTM1, a protein
that links ubiquitinated protein aggregates to LC3 [12].
Once the autophagolysosome has formed, acid hydro-
lases (particularly, the cathepsins) degrade the seques-
tered material, and the substrates are recycled for
biosynthetic processes [13,14].utophagy process. The first step starts with the vesicle nucleation
of an autophagosome that entraps cellular materials. The core
rs, are shown in the inset. The kinase activity of PI3k class III can be
ion of bcl-2 with beclin 1 precludes the formation of the beclin 1-PI3k
sphorylation of beclin 1 disrupts the bcl-2/beclin 1 interaction, and
cleation and expansion, a lipidated LC3-II isoform is included in both
rucial role in the generation of LC3 II from LC3 I. Other Atg proteins
(i.e., conjugation with phosphatydil choline) and membrane insertion
agosome with several endosomes and lysosomes to form the
lysosome pH (e.g. Chloroquine, Bafilomycin A1). The third step consists
lases, and subsequent release of substrates (essentially AA, aminoacids;
e inhibited by protease inhibitors (e.g., Leupeptin, Pestatin A) or by
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The biochemical regulation of autophagy has been
the subject of excellent recent reviews, to which the
readers may refer for a detailed description [15,16]. A
variety of protein- and lipid-kinases, protein- and lipid-
phosphatases, and mono and trimeric GTPases control
the induction and progression of autophagy [15-19]. A
simplified network of the main regulatory pathways is
illustrated in Figure 2. Classically, the starting signal for
the formation of the autophagosome is the synthesis of
phosphatydil-inositol-3-phosphate (PI3P) molecules by
the PI3k class III kinase (also known as Vps34), which
becomes active upon interaction with Beclin 1Figure 2 Signaling pathways impinging on autophagy. The scheme illu
of autophagy. Essentially, growth factors activate the mTORC1 complex (tro
inhibition of the ULK1(ATG1) complex and prevents the induction of autop
this pathway through the inhibition of the Ras-Mek-Erk pathway, and by di
shown in the scheme). The lipid-kinase activity of PTEN prevents the activa
inhibition of autophagy exerted by this pathway. This tonic inhibition can b
Rapamycin. Hypoxia and mitochondrial oxidative stress inhibit mTOR throu
acid deprivation) activates the JNK pathway, which ends with the phospho
interactome. Once activated, Vps34 produces PI3P, which acts as a platform
membrane nucleation and elongation. A genotoxic stress activates p53 and
autophagy proteins (e.g., DRAM, UVRAG, cathepsin D). However, high levels
the inhibition of autophagosome formation.(homologue of Vps30/Atg6) [20, see also Figure 1].
By contrast, the production of phosphatydil-inositol-
3,4,5-phosphate (PIP3) by class I PI3k keeps basal
autophagy at low level through the activation of the
Akt pathway [21]. The lipid phosphatase activity of the
oncosuppressor PTEN, which removes the phosphate
in position 3 from PIP3, counteracts the activation of
Akt and therefore allows autophagy [22]. A crucial
player in the regulation of autophagy is mTOR (mam-
malian Target of Rapamycin), whose kinase activity
inhibits Atg1/ULK1 and the formation of the autop-
hagy interactome [18]. While the Akt pathway nega-
tively regulates autophagy through the activation ofstrates the network of the principal kinases involved in the regulation
ugh the inhibition of the TSC1/TSC2 complex), and this results in the
hagy. The abundance of aminoacids also results in down-regulation of
rect activation of mTOR through the RagA/B GTPases complex (not
tion of the Akt-mTOR pathway, and therefore removes the tonic
e also removed artificially by pharmacologic inhibition of mTOR with
gh the action of AMPk on the TSC1/TSC2 complex. Starvation (amino
rylation of bcl-2, thus allowing the formation of the autophagy
for other autophagy proteins involved in autophagosomal
other transcription factors (e.g., TFEB) that promote the synthesis of
of cytoplasmic p53 (localized in the endoplasmic reticulum) result in
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ATP, inhibits mTOR and directly activates Atg1
(homologue of ULK1), thus promoting autophagy in
response to stressors [23]. It follows that activation of
autophagy may occur in the presence of phosphory-
lated Akt, provided that mTOR is inactivated [24]. It
is to be mentioned that autophagy may also be
induced bypassing the mTOR control, for instance by
increasing the level of Inosytol-tri-phosphate (IP3)
[25]. Remarkably, at variance of the canonical pathway
described above, mammalian cells can activate alterna-
tive pathways for autophagic degradation in which cer-
tain autophagy proteins (e.g., Beclin-1, Vps34, Atg5,
Atg7, ULK1) are dispensable (reviewed in [26]).
Simplifying, amino acids and growth factors keep
mTOR active and prevent the hyper-induction of autop-
hagy, whereas nutrient shortage and energy depletion in-
crease the level of basal autophagy (Figure 2).
Functional significance of autophagy in normal and in
cancer cells
Autophagy accomplishes two fundamental physiological
activities: (1) it constitutively degrades and recycles re-
dundant and aged molecules and organelles, and (2) it
destroys abnormal and potentially harmful molecular
and cellular components [15]. To understand the role of
autophagy in cell physiology and pathology it is funda-
mental to distinguish basal and induced autophagy.
Basal (constitutive) autophagy prevents unwanted and
unnecessary increases in cell mass by eliminating ex-
uberant and exceeding cellular structures, thus greatly
contributing to cell homeostasis. In normal cells, consti-
tutive autophagy is subjected to modulation depending
on the metabolic state of the cell: while in growing cells
active mTOR exerts a tonic inhibitory control that keeps
constitutive autophagy at low basal level, in normal qui-
escent cells constitutive autophagy is up-regulated to
equilibrate synthesis in order to allow the macromolecu-
lar turnover without net increases in cell mass. On de-
mand, autophagy can be transitorily hyper-induced, for
instance to meet the need to recover from nutrient or
energy depletion, or to contrast the accumulation of
damaged molecules and organelles. In cancer cells
autophagy is clearly dysregulated. The strict connection
between autophagy and carcinogenesis is supported by
the fact that numerous oncogene and oncosuppressor
proteins regulate both processes [27]. Autophagy plays a
complex and apparently contradictory role in the various
phases of cancer development and progression. In fact,
by avoiding the accumulation of damaged molecules and
organelles that may increase the probability of oxidative
stress-mediated DNA mutation, basal autophagy pre-
vents cell transformation [28]. Consistently, loss-of-
function of genes that positively regulate autophagy,such as Beclin-1 [29,30] or PTEN [31], predisposes to
spontaneous cancers. On the other hand, when a che-
motherapeutics induces oxidative stress and DNA dam-
age or when defective vascularization determines
hypoxia and starvation, the up-regulation of autophagy
enables cancer cells to overcome the metabolic stress
[32,33]. In such circumstances, up-regulation of autop-
hagy associated with down-regulation of apoptosis
contributes to chemoresistance. Further, a long-lasting
up-regulation of basal autophagy may favor a senescent/
dormancy state in cancer cells [34], and likely in cancer
stem cells as well, that resist to radio- and chemotherapy,
and could be re-activated and give rise to recurrent
cancer.
Epigenetic regulation of autophagy: the role of histone
deacetylases, of microRNAs, and of the tumor
microenvironment
Besides the fact that autophagy can be dys-regulated as a
consequence of mutations in autophagy-related genes,
including oncogenes and oncosuppressor genes, the pos-
sibility that the actual level of autophagy in cancer cells
is dynamically influenced by epigenetic factors should be
taken into account. The principal intrinsic epigenetic
regulation occurs at transcriptional level, through modu-
lation of DNA methylation and histone acetylation,
and at post-transcriptional level through microRNA
(miRNA)-mediated degradation of mRNA. For instance,
the expression of ARH1 gene, an oncosuppressor that
regulates autophagy (see below), is repressed in many
cancers, including ovarian cancers, due to hyper-
methylation of its promoter [35]. Moreover, certain miR-
NAs, a class of small non-coding RNAs, have recently
emerged as important epigenetic modulators of autop-
hagy in cancer cells (reviewed in [36]). The mRNA of
several autophagy-related genes contains, in fact, the tar-
get sequence for miRNAs belonging to different families,
with either oncosuppressive or oncogenic activities. For
instance, Beclin-1 mRNA can be targeted by oncosup-
pressive members of the miR30 family [37] and by onco-
genic miR-376b [38]; the mRNA of ATG4C is down-
regulated by oncogenic miR-376b [38] and that of
ATG4D by oncosuppressive miR-101 [39]; the mRNA of
p62/SQSTM is targeted by miR-17/20/93 and miR106
[40], while the expression of MAP-LC3 can be affected
by miR196 [41], and the translation of ATG7 mRNA is
suppressed by miR375 [42]. Finally, autophagy can be
modulated through modulation of hystone acetylation/
deacetylation by the hystone deacetylases HDAC4 and
HDAC5, which are targeted by miR-9-3p [43]. To be
noted, HDAC6 promotes the autophagic flux by regulat-
ing the acetylation status of cytoskeleton proteins [44].
Additional mechanisms of epigenetic regulation in-
volve extracellular signals. In fact, microenvironmental
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ity, cytokines, hormones and growth factors) and the
physical-metabolic interaction with surrounding cells
(inflammatory cells, fibroblasts) in the matrix greatly in-
fluence the autophagy compliance of the tumor cell [45-
47]. The scarce vascularization in the most inner portion
of the tumor determines a situation of hypoxia and star-
vation, which cause the activation of autophagy driven
by the Hypoxia Inducible Factor HIF-1α [48] and by
AMPk [49], thus conferring a survival advantage to can-
cer cells. On the other hand, in the highly vascularized
area of the tumor, the presence of nutrients limits autop-
hagy and favors the growth of cancer cells. In addition,
cancer associated fibroblasts, inflammatory cells (espe-
cially type-2 macrophages) and cytokines (e.g., IL-1β,
TNF-α and IL-6) have been shown to affect the regula-
tion of autophagy in cancer cells through induction of a
metabolic stress [47,50-52].
Involvement of autophagy in ovarian cancer
According to genetic and pathologic features, epithelial
ovarian cancer are classified in Type I tumors, character-
ized by a variety of somatic mutations or amplification/
deletion of oncogenes or oncosuppressors including K-
RAS, B-RAF and PTEN, and Type II tumors, which are
chromosomally unstable, and present with mutated or
deleted TP53 (in more than 80% of the cases) and BRCA
inactivation (in up to 30% of the cases) [53,54]. Type-1
ovarian cancers comprise clinically indolent, low grade
serous and endometrioid carcinomas, clear cells and
mucinous carcinomas; type-2 ovarian cancers comprise
aggressive, high-grade serous and endometrioid carcin-
omas, malignant mixed mesodermal carcinomas, and
undifferentiated carcinomas [53,54]. Besides the genetic
alterations, it is now becoming clear that also epigenetic
mechanisms play a role in the development of ovarian
cancer [55]. Yet, the mechanisms involved in epithelial
ovarian cancer pathogenesis and progression are still
largely obscure. Autophagy dysregulation might play an
important role in the pathogenesis, as well as in resist-
ance to radio- and chemotherapeutic treatments and in
dormancy in ovarian cancer. Indeed, a number of onco-
genes and oncosuppressor genes have been found
deregulated in ovarian cancers because of genetic or epi-
genetic alterations [56,57], and many of these potentially
impact on autophagy regulation. Furthermore, a plethora
of proteins whose expression has been found altered in
ovarian cancers may directly or indirectly affect autop-
hagy at different level. Schematically, the genes found
altered in ovarian cancer that have an impact on autop-
hagy belong to: (1) the oncosuppressors PTEN, ARHI
and p53, that regulate autophagy, apoptosis and dor-
mancy; (2) the components of the autophagy machinery
LC3, beclin-1 and DRAM; (3) the growth factor andnutrient sensor signaling pathways, which include the
class I PI3-k/Akt/mTOR and the Ras/Raf/ERK pathways.
As compared to benign hyperplastic tissues and bor-
derline ovarian tumors, poorly differentiated and highly
malignant ovarian cancer cells were shown to express
very low level of the autophagy protein LC3 [58], indi-
cating that LC3-labeled autophagosomes do not accu-
mulate in highly aggressive ovarian cancers. Whether
this phenomenon underlies the inability to form autop-
hagosomes or rather reflects their efficient removal by
the lysosomal system remains to be elucidated. Mutation
and deletion of the oncosuppressor P53 gene has been
reported in 60–80% of both sporadic and familial ovar-
ian cancers [56]. DNA-binding deficient p53 mutants
are unable to sequester bcl-2 or bcl-XL, and display a
dominant negative activity. Bcl-2 can inhibit the forma-
tion of the autophagy interactome by interacting with
beclin 1 [20], and therefore the over-expression of such
mutated p53 in ovarian cancer cells may indirectly im-
pact on autophagy. In addition, p53 mutants that per-
manently localizes in the cytoplasm have been shown to
inhibit autophagy [59]. ARH1 (Aplasia Ras Homolog
member I; also known as DIRAS3), which encodes a
ras-homolog 26 kDa GTPase, is a tumor suppressor
gene imprinted down-regulated in ovarian cancers [60].
Re-expression of ARH1 suppresses proliferation, motility
and angiogenesis [61,62] and promotes cell death [63] in
ovarian cancer cells. Of note, ARH1 protein has recently
been shown to up-regulate autophagy (through inhib-
ition of the mTOR pathway) and to induce autophagy-
dependent dormancy in ovarian cancer cells [34]. The
latter finding implies that re-activation of ARHI can en-
able ovarian cancer cells to overcome metabolic stress
and to survive in a dormant state in appropriate tumor
microenvironment. As stated above, active mTOR exerts
a tonic inhibition on basal autophagy. It is intriguing, in
this respect, the finding that a hyper-active status of
mTOR is associated with a poor prognosis in ovarian
carcinoma patients [64]. Sustained up-regulation of the
class I PI3k-Akt-mTOR axis in ovarian cancers may
arise from activating mutation or duplication of genes
coding for the Tyrosin Kinase Receptors EGFR and
PDGFR, for PI3kCA or Akt [65,66], as well as by inacti-
vating mutations of PTEN [67] or hyper-expression of
the PTEN-regulator protein DJ-1 [68]. BECLIN 1 has
been the first oncosuppressor gene that proved the link
between autophagy and cancerogenesis [69]. Of note,
monoallelic deletion of BECLIN 1 is found in more than
50% of sporadic ovarian cancers [69]. Accordingly, the
expression of beclin 1 was found down-regulated in
ovarian cancers, compared to benign lesions [58]. Con-
sistent with a role of autophagy-active beclin 1 in ovar-
ian cancer progression, we found that hyper-expression
of both beclin 1 and LC3 in ovarian cancer cells was
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patients (Peracchio et al., unpublished data; Figure 3).
Another autophagy-regulator gene associated with ovar-
ian cancer progression is DRAM (Damage-Regulated
Autophagy Regulator), a p53-trancribed gene that
codes for a lysosomal-associated protein involved in
apoptosis and autophagy [70]. Recently, it has been
reported that the homologous DRAM2, which also
induces autophagy [71], is expressed at very low level
in aggressive ovarian tumors [72]. Transgenic over-
expression of PEA-15, the 15 kDa Phospho-Enriched
protein in astrocytes, has recently been shown to in-
duce autophagy and non-apoptotic cell death in ovar-
ian cancer cells through the activation of the ERK
pathway [73]. It is intriguing to observe that women
bearing an ovarian cancer with high level of expres-
sion of PEA-15 have an overall survival longer than
those bearing a low-PEA15-expressing cancer [73]. In
aggregate, the data so far available consistently indi-
cate that an intrinsic defect in the activation of
autophagy leads to a more aggressive progression of
ovarian cancer.Figure 3 Immunodetection of autopahgy proteins in ovarian cancer t
and LC3 (panel B) appears as discrete puncta (indicative of protein clusteriz
beclin 1 and of LC3 (positivity in > 40% of cancer cells) was found to correl
up). Immunohistochemistry of beclin 1 in a positive (panel C) and in a neg
or absence of beclin 1 aggregates can be appreciated in the high-magnificEpigenetic factors that impinge on autophagy in ovarian
cancer
As mentioned above, autophagy in cancer cells is sub-
jected to fluctuations depending on extracellular stimuli,
the availability of oxygen and nutrients, and also on the
actual expression of certain microRNAs. Ovarian cancer
cells release chemotactic cytokines and growth factors
that recruit fibroblasts, endothelial cells and macro-
phages, which in turn contribute with their own secre-
tions to form a dynamic tumor microenvironment
[74,75]. A number of inflammatory-related proteins ab-
normally present in the tumor context or in the ascitic
fluid, and associated with ovarian cancer progression,
could directly or indirectly affect autophagy. For in-
stance, TNFα, a cytokine involved in ovarian cancer
growth and metastasis [74], is a potent activator of NF-
kB, which in turn activates the anti-apoptotic and anti-
autophagic Akt/mTOR pathway. IL-6 is a pro-
inflammatory cytokine highly expressed in the tumor
context of type-2 ovarian cancers and in ascitic fluid,
and its level correlates with poor prognosis in ovarian
cancer patients [76,77]. IL-6 promotes VEGF-mediatedissue sections. Immunofluorescence positivity for beclin 1 (panel A)
ation) in the cytoplasm of cancer cells. A high level of expression of
ate with good prognosis (CR, complete remission at 5 years of follow
ative (panel D) case is also shown (magnification 420x). The presence
ation (1050x) area shown in the insets.
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type-2 ovarian cancers [77]. Lysophosphatidic acid
(LPA), abundantly released by ovarian cancer cells, is
known to contribute to ovarian cancer aggressiveness by
stimulating the synthesis of IL-6 and of VEGF [78,79],
among others. Of note, while IL-6 acts as an inducer
[80], LPA was shown to inhibit autophagy induced by
serum deprivation in prostate cancer cells [81]. These
data outline how the microenvironment and the cytokine
network dynamically affect autophagy in ovarian cancer
cells. In the epigenetic control of autophagy, a further
level of complexity is brought by the dynamic changes in
the expression of miRNAs. The profile of miRNAs pat-
tern in ovarian cancer cells varies during development
and progression phases [82-84]. Although a thorough
analysis of miRNA-mediated regulation of autophagy in
ovarian cancer cells has not yet been performed, we can
speculate in this sense based on the information avail-
able. For instance, miR-30a, which negatively regulates
the expression of Beclin 1 [37], was found down-
regulated in samples from relapsing patients diagnosed
with stage I ovarian cancer [85]; and miR-101, which
represses the expression of the autophagy protein Atg4
[39], was found down-regulated in ovarian cancer com-
pared to normal tissue [86]. MiR-101 targets also the
mRNA of STMN1 and RAB5A [39]. Of note, stathmin
over-expression showed a significant association with
poor prognosis in ovarian cancer patients [87], and
Rab5A was shown to promote cell proliferation in ovar-
ian cancer [88]. Finally, miR-214 and mir-21, respectively
associated with the chemoresistant phenotype [89] and
the metastatic potential of ovarian cancer cells [90], have
been shown to target PTEN, the oncosuppressor known
to positively regulate autophagy and to be mutated or
deleted in a vast majority of ovarian carcinomas. With re-
gard to the transcriptional level of epigenetic regulation
of autophagy in ovarian cancer, the oncosuppressors
PTEN, ARH1 and DAPk (Death-associated protein kin-
ase) merit to be mentioned. The hyper-methylation of
PTEN promoter is not a frequent finding in ovarian can-
cer specimen [91]. By contrast, ARH1 and DAPk are
among the most frequently down-regulated tumor sup-
pressors in ovarian cancers due to promoter methylation
[35,91]. Under stressful conditions, DAPk phosphorylates
beclin-1, promoting its dissociation from bcl-2, and thus
inducing autophagy [92].
Clinical implications and future perspectives
Targeting of the autophagy pathway is being under evalu-
ation as a new anti-cancer therapeutic option [93-95].
Data in the literature show that both autophagy enhancer
and autophagy inhibitor drugs may elicit beneficial
effects by inducing cancer cell death. This apparent
contradiction could be explained considering thecomplex role that autophagy plays in cancer cells in the
different phases of carcinogenesis, and in dependence of
the tumor context. In fact, while at the precancerous
stage an autophagy defect would facilitate genomic in-
stability and tumor development, in growing tumors the
up-regulation of autophagy compensates for the limited
nutrient supply and helps to face genotoxic and meta-
bolic stresses [96,97]. The latter phenomenon constitutes
the rationale for using inhibitors of the late step of the
autophagy process (e.g., chloroquine) together with trad-
itional anti-neoplastics [93-95]. In certain circumstances,
the excessive and sustained up-regulation of autophagy
(for instance under prolonged starvation, oxidative stress
or metabolic impairment) has been associated with cell
death [98,99]. This observation constitutes the rationale
for using drugs that induce autophagy, such as rapamycin
and its analogs [93-95]. The switch from a pro-survival
to a pro-death outcome of autophagy activation could
also be exploited in cancer therapy. Relevant to the
present study, a phase II clinical trial for the treatment of
endometrioid ovarian cancer with an mTOR inhibitor is
currently ongoing [100]. At present, 22 clinical trials (of
which 2 are terminated) are using rapamycin or its ana-
logs in combination with other drugs for the treatment
of ovarian cancer (http://www.clinicaltrials.gov). Another
drug that has been proposed as a molecular therapeutics
for the treatment of ovarian cancers is the anticonvulsant
Valproic acid (VPA), which acts as a histone-deacetylase
inhibitor [4]. At present, 2 ongoing clinical trials are
using VPA alone or in combination with Carboplatin for
the treatment of ovarian cancer (http://www.clinical-
trials.gov). VPA and tubacin (another histone deacety-
lase) kill ovarian cancer cells at doses that specifically
inhibit HDAC6 [101], which is known to favor the fusion
of autophagosomes with lysosomes through the deacety-
lation of tubulin and actin [44]. Thus, targeting autop-
hagy might be a strategy to combat ovarian cancers that
have developed chemoresistance to traditional antiblastic
therapies. However, it must be kept in mind that the effi-
cacy of autophagy-based therapies strictly depends on
the actual level of ongoing autophagy in the tumor cells,
which is dictated by genetic mutations, but also influ-
enced by the epigenetic regulation of relevant genes, as
mediated by the tumor microenvironment (namely the
vascularization and the extent of the infiltration by fibro-
blasts and immuno-inflammatory cells) and by certain
miRNAs. The unraveling of clinical implications of gen-
etic and epigenetic factors involved in autophagy dysre-
gulation in ovary cancer might hopefully open the way to
new diagnostic and therapeutic approaches for this ma-
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